Cargando…

Scientific rationale for developing potent RBD-based vaccines targeting COVID-19

Vaccination of the global population against COVID-19 is a great scientific, logistical, and moral challenge. Despite the rapid development and authorization of several full-length Spike (S) protein vaccines, the global demand outweighs the current supply and there is a need for safe, potent, high-v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleanthous, Harry, Silverman, Judith Maxwell, Makar, Karen W., Yoon, In-Kyu, Jackson, Nicholas, Vaughn, David W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553742/ https://www.ncbi.nlm.nih.gov/pubmed/34711846 http://dx.doi.org/10.1038/s41541-021-00393-6

Ejemplares similares

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™
por: Xu, Senyu, et al.
Publicado: (2023)

Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2
por: Lei, Hong, et al.
Publicado: (2020)

Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants
por: Bajoria, Sakshi, et al.
Publicado: (2022)

Antibodies and Vaccines Target RBD of SARS-CoV-2
por: Min, Long, et al.
Publicado: (2021)

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
por: Junker, Daniel, et al.
Publicado: (2022)

Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice
por: Song, Shuo, et al.
Publicado: (2022)

Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines
por: Dickey, Thayne H., et al.
Publicado: (2023)

Scientific rationale for a higher dose of nusinersen
por: Finkel, Richard S., et al.
Publicado: (2022)

Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants
por: Mittal, Nidhi, et al.
Publicado: (2023)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine
por: Li, Chia-Jung, et al.
Publicado: (2023)

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
por: Fan, Chengcheng, et al.
Publicado: (2022)

Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
por: Zhang, Ting, et al.
Publicado: (2023)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
por: Niazi, Sarfaraz
Publicado: (2022)

The Scientific Rationale for the Introduction of Renalase in the Concept of Cardiac Fibrosis
por: Stojanovic, Dijana, et al.
Publicado: (2022)

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
por: Janson, Christer, et al.
Publicado: (2017)

Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro
por: Pan, Xiaoyan, et al.
Publicado: (2020)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

Copper-Heparin Inhalation Therapy To Repair Emphysema: A Scientific Rationale
por: Janssen, Rob, et al.
Publicado: (2019)

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
por: Amanat, Fatima, et al.
Publicado: (2021)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018(TM) Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen
por: Bajoria, Sakshi, et al.
Publicado: (2023)

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B
por: Aguilar, Julio Cesar, et al.
Publicado: (2022)

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
por: Chen, Yuxin, et al.
Publicado: (2021)

Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response
por: Lin, Ting-Wei, et al.
Publicado: (2022)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

Sucralose Non-Carcinogenicity: A Review of the Scientific and Regulatory Rationale
por: Berry, Colin, et al.
Publicado: (2016)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
por: Timofeeva, Natalia, et al.
Publicado: (2021)

Scientific Rationale for the Treatment of Cognitive Deficits from Long COVID
por: Fesharaki Zadeh, Arman, et al.
Publicado: (2023)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
por: Liu, Zheng, et al.
Publicado: (2022)

Mutated trimeric RBD vaccines: a platform against variants of concern
por: Aparicio, Belén, et al.
Publicado: (2023)

Structural Basis of Binding and Rationale for the Potent Urease Inhibitory Activity of Biscoumarins
por: Lodhi, Muhammad Arif, et al.
Publicado: (2014)

United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
por: Elliott, C. Gregory, et al.
Publicado: (2019)

Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates
por: Zhao, Hui, et al.
Publicado: (2021)

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
por: Zhang, Jing, et al.
Publicado: (2022)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_doka3iq16t2a1bnkonh4cd3r4p